Please click here for the safety profile and talk to your health care professional
The patient should be counselled about the GI AEs
The weight loss timeline for semaglutide shows that most people resume losing weight once they reach therapeutic doses, typically by weeks 8 to 12
Model based estimates based on an analysis of covariance model including treatment and stratification groups (gender, Tanner stage group) and the interaction between stratification groups as factors and baseline value as a covariate
Identifying High-Risk Patients Pre-existing conditions that may increase NAION risk with GLP-1 use include: Diabetes, especially long-standing or poorly controlled Hypertension Hyperlipidemia Sleep apnea History of previous NAION in one eye Age is a significant factor, with individuals over 50 at higher risk
If youre exploring weight loss options, you may have come across Wegovy, an injectable treatment that has been proven to enhance results when paired with a healthy diet and regular exercise
